CompletedEUCTR 2007-003159-36

An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patient...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesDepression

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Finland · France and 1 more location
Study phase: Phase 3

Get this study by email

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 615
Sponsor: sanofi-aventis recherche & développement
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: France, Finland, Sweden
Age range: Not clearly listed
Official registry ID: EUCTR 2007-003159-36
Official title: Show the full official title
An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patient...

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Finland · France · Sweden

Registry details

Historical country statuses

Finland — Completed
France — Completed
Sweden — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is sanofi-aventis recherche & développement.

Want to explore more studies?

Explore studies